Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Applied Therapeutics, Inc. (APLT)

[Click here to learn more about the investigation]

On November 27, 2024, Applied Therapeutics disclosed that it had received a Complete Response Letter ("CRL") from the U.S. Food and Drug Administration ("FDA") regarding the New Drug Application ("NDA") for the Company's Classic Galactosemia drug, govorestat, stating that "[t]he CRL indicates that the FDA completed its review of the application and determined that it is unable to approve the NDA in its current form, citing deficiencies in the clinical application." On this news, Applied Therapeutics' stock price fell $6.54, or 76.3%, from $8.57 per share on November 27, 2024, to close at $2.03 on November 29, 2024.

If you purchased or otherwise acquired Applied Therapeutics securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs' law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm's efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/233530